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Available online 12 November 2016For nearly a century, aluminum salts have been the most widely used vaccine adjuvant formulation, and have
thus established a history of safety and efﬁcacy. Nevertheless, for extremely challenging disease targets such as
tuberculosis or HIV, the adjuvant activity of aluminum salts may not be potent enough to achieve protective ef-
ﬁcacy. Adsorption of TLR ligands to aluminum salts facilitates enhanced adjuvant activity, such as in the human
papilloma virus vaccine Cervarix®. However, some TLR ligands such as TLR7/8 agonist imidazoquinolines do not
efﬁciently adsorb to aluminum salts. The present report describes a formulation approach to solving this chal-
lenge by developing a lipid-based nanosuspension of a synthetic TLR7/8 ligand (3M-052) that facilitates adsorp-
tion to aluminum oxyhydroxide via the structural properties of the helper lipid employed. In immunized mice,
the aluminum oxyhydroxide-adsorbed formulation of 3M-052 enhanced antibody and TH1-type cellular im-
mune responses to vaccine antigens for tuberculosis and HIV.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Since Glenny's pioneering work in the early 20th century [1], alumi-
num salts have become the most widely used adjuvants in human vac-
cines, generating an unrivalled history of safety and suitability with
various vaccine antigens. Aluminum salts generally consist of semi-
crystalline nano- and micro-particles with a large surface area and a
high charge density. Theymay bemost effective as adjuvants when vac-
cine antigens are optimally adsorbed to the surface of the aluminum salt
particles [2]. Aluminum salts are effective in boosting antibody re-
sponses to vaccine antigens, but there is little indication that they sub-
stantially augment cellular immunity to vaccine antigens. Induction of
effective cellular immunity is likely essential for developing effective
vaccines for several diseases including tuberculosis, HIV, and malaria.
Therefore, the adsorption of additional immunostimulants to aluminum
salts should also be a paramount consideration in vaccine formulation
development. Thus, an important advancement in the clinical use of ad-
juvants occurred in 2009when the US FDA approved GlaxoSmithKline's
human papilloma virus vaccine Cervarix® for human use in 2009;. This is an open access article underCervarix® contains AS04, an adjuvant system consisting of the Toll-
like receptor 4 (TLR4) ligandmonophosphoryl lipid A (MPL®) adsorbed
to aluminum oxyhydroxide, resulting in potent adjuvant activity [3].
Combining TLR ligands with aluminum salts is an attractive ap-
proach given that aluminum salts have an established safety andmanu-
facturability history, are familiar to regulatory agencies, and are more
amenable to a stable single vial liquid presentation that can promote
Th1-type immunity when combined with a TLR ligand [4]. Moreover,
adsorption to aluminum of TLR ligands co-localizes antigen and adju-
vant, and facilitates reduction of antigen and/or TLR ligand dose [5–7].
Therefore it is of high interest to develop aluminum salt-based formula-
tions of other pattern recognition receptor (PRR) ligands (besides TLR4
agonists) to enhance antigen-speciﬁc Th1-type immunogenicity and
protective efﬁcacy [5,8,9]. Some PRR ligands, such as the TLR4 ligand
MPL® and the TLR9 ligand CpG oligonucleotides, adsorb to some alumi-
num salts due to physicochemical structure compatibility. For example,
aluminum oxyhydroxide is positively charged and adsorbs antigens or
TLR ligands due to phosphate ligand exchange and/or electrostatic in-
teractions [2,10]. In contrast to the TLR4 ligands (which often contain
phosphate groups) or nucleotide-based TLR9 and TLR3 ligands (which
are negatively charged), other PRR ligands of interest including the
TLR7/8 agonist imidazoquinolines may not contain structural moieties,
such as phosphate groups or anionic charge, that would promotethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
99C.B. Fox et al. / Journal of Controlled Release 244 (2016) 98–107adsorption to aluminum oxyhydroxide. The situation is further compli-
cated for insoluble lipid-based PRR ligands, which must ﬁrst be formu-
lated into aqueous suspensions prior to adsorption to aluminum salt
[10].
In earlier work, we developed an aqueous nanosuspension of an in-
soluble synthetic TLR4 ligand (GLA) by formulating with a phosphati-
dylcholine to form GLA-AF, which was shown to adsorb to aluminum
oxyhydroxide through phosphate ligand exchange [10]. Characteriza-
tion of the adsorption interactions between aluminum oxyhydroxide
and the phospholipid excipient component of GLA-AF led us to hypoth-
esize that helper lipids could promote the adsorption of insoluble PRR
ligands to aluminum oxyhydroxide even if the PRR ligand does not con-
tain a phosphate or other anionic group.Moreover, the versatility of this
approach could allow adsorption of the same PRR ligand to different
types of aluminum salts depending on the structure of the helper lipid
with which it is complexed. We have selected an insoluble TLR 7/8 li-
gand that does not contain a phosphate or other anionic group to dem-
onstrate this approach.
Appropriate formulation of TLR7/8 agonists is an attractive adjuvant
development approach for several reasons includingmanufacturability,
induction of potent TH1 responses, and prior use in an FDA-approved
product. The ability of imidazoquinolines to target TLR7 and/or TLR8
to generate enhanced TH1-type innate immune responses, including
IgG2 antibodies in mice, has been documented in the literature
[11–13]. As synthetic small molecules, imidazoquinolines can be
manufactured cost effectively and at high purity. The TLR7 ligand
imiquimod is the active component in the topical cream Aldara®,
approved for human immunotherapeutic use to treat skin cancer and
genital warts. However, injected imidazoquinolines as vaccine adju-
vants have not progressed beyond early phase clinical testing. Due
to their small size, it is hypothesized that soluble unformulated
imidazoquinolines such as R848 rapidly diffuse from the injection site,
causing systemic immune activation rather than localized stimulation.
For this reason, strategies to “slow down” imidazoquinoline diffusion
such as covalent conjugation to vaccine antigens or encapsulation
in particulate formulations have shown promise in preclinical testing
[8,14–17]. Smirnov et al. describe a chemical synthesis approach in
which the addition of an 18-carbon chain to an imidazoquinolineFig. 1. Chemical structure of 3M-05structure maintains local adjuvant activity but does not generate the
systemic responses evident with non-lipidated structures such as
R848 [16]. This new molecule, called 3M-052 (Fig. 1), is thus more
amenable to incorporation in lipid-based formulations such as
nanosuspensions, liposomes, or emulsions. In the present work, we
describe a formulation approach involving the development of
nanosuspensions involving helper lipids with phosphate or other
charged groups to modulate the adsorption interactions between the
synthetic insoluble TLR7/8 ligand 3M-052 [16] and aluminum salts in
order to create a new vaccine adjuvant formulation that enhances anti-
body and cellular immunogenicity to co-adsorbed recombinant tuber-
culosis or HIV vaccine antigens.2. Materials and methods
2.1. Adjuvant formulation materials
Synthetic 1,2-dilauroyl-sn-glycero-3-phosphcocholine (DLPC), 1,2-
dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dipalmitoyl-
sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine
(DOPC), 1,2-dilauroyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DLPG),
1,2-dimyrsitoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DMPG), 1,2-
dipalmitoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DPPG), 1,2-
distearoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DSPG), 1,2-
dioleoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DOPG), 1,2-
distearoyl-3-trimethylammonium-propane (DSTAP), 1,2-dipalmitoyl-
3-trimethylammonium-propane (DPTAP), and glucopyranosyl lipid ad-
juvant (GLA, also known as PHAD®) were purchased from Avanti Polar
Lipids Inc. (Alabaster, AL). Polysorbate 80was purchased from J.T. Baker
(San Francisco, CA). Poloxamer 188 was purchased from Spectrum
Chemical (Gardena, CA). Saline solution (0.9% w/v) was purchased
from Teknova (Hollister, CA). CpG ODN was obtained from Avecia
(Milfrod, MA). Alhydrogel® ‘85’ and AdjuPhos® were purchased from
E.M. Sergeant Pulp & Chemical Co. (Clifton, NJ). 3M-052 (S-36862)
was synthesized by 3M Drug Delivery Systems. The chemical structure
has been previously disclosed [16].2 and screened helper lipids.
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Aqueous nanosuspensions were manufactured by dispersing 3M-
052 or GLA with each lipid excipient (see Fig. 1) at a 1:2 M ratio
(adjuvant:lipid), in chloroform or a mixture of chloroform, methanol,
and water. The solvent was then evaporated using a Genevac EZ-2 cen-
trifugal evaporator (Stone Ridge, NY) for several hours or overnight. The
dried ﬁlms were rehydrated in ultrapure water, then sonicated in a
Crest powersonic CP230D (Trenton, NJ) sonicating water bath at
~60 °C for up to several hours or until the formulationswere translucent
with no visible particles. To formulate alum-containing compositions,
the aqueous nanosuspensions were mixed with Alhydrogel® or
AdjuPhos®. For the immunogenicity studies, recombinant vaccine anti-
gens (ID93 for tuberculosis or FLSC for HIV) were mixed together with
the nanosuspension, alum, and the indicated diluent to deliver an anti-
gen dose of 0.5 μg or 10 μg, a 3M-052 dose of 0.1–10 μg, and an alumi-
num dose of 100 μg, in a 100-μl total volume as indicated in the ﬁgure
captions. ID93 is a recombinant fusion protein containing four tubercu-
losis antigens [18]. FLSC is a recombinant antigen containing a full-
length single-chain gp120-CD4 complex [19].
2.3. Adjuvant formulation characterization and stability
Aqueous nanosuspensions were characterized for particle size by
dynamic light scattering (DLS) using the Malvern Instruments
(Worcestershire, UK) Zetasizer Nano-S or –ZS. Aqueous nano-
suspensions were diluted 1:10 or 1:100 fold in water in a polystyrene
cuvette prior to analysis, which consisted of three measurements
resulting in a scattering intensity-biased average diameter value report-
ed as the Z-ave. Zeta potential was measured using the Zetasizer Nano-
ZS using a disposable capillary cell, with nine consecutive measure-
ments collected from each sample prepared at 1:10 dilution in water.
In general, 3M-052 concentration was measured by UV absorbance at
322.5 nm after diluting formulations 1:20 into ethanol:HCl (98:2 v:v)
and comparing to a standard curve. The dilution into organic solvent
removes potential interference from light scattering of the nano-
suspension particles. However, for the 3M-052 binding isotherm,
where maximum sensitivity was desired, no dilution was performed
for the samples or the standards. CpG concentration was measured by
UV absorbance at 260 nm after 1:20 dilution into ethanol:HCl. GLA con-
centration was measured by reverse-phase HPLC with an C18 column
(Atlantis T3 or Agilent XBridge) and charged aerosol detection (CAD)
using amethanol:chloroform:watermobile gradient as described previ-
ously [20]. To detect unbound TLR ligand, alum-containing formulations
were centrifuged brieﬂy as indicated and the supernatant assayedbyUV
absorbance or HPLC-CAD. Unless otherwise noted, centrifugation time
was 5 min at 16,000 ×g.
2.4. Cryo-transmission electron microscopy (cryoTEM) imaging
Samples were preserved in vitriﬁed ice supported by holey carbon
ﬁlms on 400-mesh copper grids. Samples were prepared by applying a
3 μl drop of sample suspension to a cleaned grid, blotting away with ﬁl-
ter paper, and immediately proceeding with vitriﬁcation in liquid eth-
ane. Grids were stored under liquid nitrogen until transferred to the
electron microscope for imaging. Electron microscopy was performed
using an FEI Tecnai T12 electron microscope, operating at 120 keV
equipped with an FEI Eagle 4 k × 4 k CCD camera. Vitreous ice grids
were transferred into the electron microscope using a cryostage that
maintains the grids at a temperature below−170 °C. Images of each
grid were acquired at multiple scales to assess the overall distribution
of the specimen. After identifying potentially suitable target areas for
imaging at lower magniﬁcations, high magniﬁcation images were ac-
quired at nominal magniﬁcations of 110,000× (0.10 nm/pixel),
52,000× (0.21 nm/pixel) and 21,000× (0.50 nm/pixel). The images
were acquired at a nominal underfocus of –2 μm (110,000×),−3 μmto –2 μm (52,000×) and –5 μm (21,000×) and electron doses of ~9–
42 e/Å2.
2.5. Antigen adsorption to aluminum salts
Binding efﬁciency of 3M-052 and ID93 or FLSC to Alhydrogel® and
AdjuPhos® was determined by UV–Vis Spectroscopy and SDS-PAGE
with silver stain. 1-mLof formulationwasprepared bymixing salinedil-
uent, antigen, 3M-052-AF (aqueous nanosuspension of 3M-052 and
DSPG), and/or aluminum salt. To determine FLSC adsorption, 30 μl of
sample supernatant was mixed with 10 μl of 4× reducing or non-
reducing LDS Sample Buffer, following which 20–25 μl was loaded into
a 10-lane SDS-PAGE gel with 15 μl of SeeBlue2 Prestained Standard.
To determine ID93 adsorption, 45 μl of sample supernatant was
mixed with 15 μl of 4× reducing LDS Sample Buffer, following which
25 μl was loaded into a 10-lane SDS-PAGE gel with 15 μl of SeeBlue2
Prestained Standard. The gels were run for 55 min at 190 V and
then placed into a ﬁxing solution of 50:40:10 EtOH:CH3COOH:H2O for
overnight. The gels were then stained according to the directions pro-
vided by Sigma-Aldrich (Saint Louis, MO) ProteoSilver Plus Silver Stain
Kit.
2.6. Animals and immunizations
C57Bl/6 and B6.129S1-TLR7tm1Flv/J (TLR7-/-) were purchased from
Jackson Laboratories (Bar Harbor, ME). Mice were immunized by intra-
muscular injection with the recombinant TB vaccine antigen ID93
(0.5 μg/dose) or the HIV vaccine antigen FSLC1 (10 μg/dose) adjuvanted
with AdjuPhos, Alhydrogel®, 3M-052 + Alhydrogel®, 3M-052 +
AdjuPhos, or GLA + Alhydrogel®. The ﬁnal adjuvant dose was 5 μg
GLA or 0.1–10 μg 3M-052 with 200 μg of AdjuPhos or Alhydrogel® in
100 μl. Mice were boosted three weeks after the ﬁrst immunization.
All mice were maintained in speciﬁc pathogen-free conditions. All pro-
cedures were approved by the IDRI Institutional Animal Care and Use
Committee.
2.7. Antibody titers
Mouse sera (N= 5/group) were prepared 21 days after immuniza-
tion by collection of retro-orbital blood into microtainer serum collec-
tion tubes (VWR International, West Chester, PA), followed by
centrifugation. Each serum sample was then analyzed by antibody cap-
ture ELISA. Brieﬂy, ELISA plates (Nunc, Rochester, NY) were coated with
2 μg/ml of the immunizing antigen in 0.1 M bicarbonate buffer and
blocked with 1% BSA-PBS. Then, in consecutive order and following
washes in PBS/Tween20, serially diluted serum samples, anti-mouse
IgG, IgG1 or IgG2c-HRP (Southern Biotech, Birmingham, AL) and
ABTS-H2O2 (Kirkegaard and Perry Laboratories, Gaithersburg, MD)
were added to the plates. Plates were analyzed at 405 nm (ELX808,
Bio-Tek Instruments Inc.,Winooski, VT). Endpoint titerswere calculated
using Prism software V6 (GraphPad). Alternatively vaginal lavage ﬂuid
was collected three weeks after the third immunization with FLSC and
analyzed for antibody titers using the same methods.
2.8. Intracellular cytokine staining
One week after the ﬁnal immunization splenocytes were isolated.
Red blood cells were lysed using Red Blood Cell Lysis Buffer
(eBioscience) and resuspended in RPMI 1640 and 10% fetal bovine
serum (FBS). Cells were plated at 2 × 106 cells/well in 96-well plates
and were stimulated for 2 h with the immunizing antigen (10 μg/ml),
or unstimulated at 37 °C. GolgiPlug (BD Biosciences) was added and
the cells were incubated for an additional 8 h at 37 °C. Cells were
washed and surface stained with ﬂuorochrome-labeled antibodies to
CD4 (clone GK1.5), CD44 (clone IM7) and CD8 (clone 53-6.7)
(BioLegend and eBioscience) in the presence of anti-CD16/32
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Cytoﬁx/Cytoperm (BD Biosciences) for 20 min. Cells were washed
twice with Perm/Wash (BD Biosciences) and stained intracellularly
with ﬂuorochrome-labeled antibodies to CD154 (clone MR1), IFN-γ
(clone XMG-1.2), IL-2 (clone JES6-5H4), TNF (clone MP6-XT22), GM-
CSF (clone MP1-22E9), IL-5 (clone TRFK5), and IL-17A (clone TC11-
18H10.1) (BioLegend and eBioscience) for 20min at room temperature.
Cells were washed and resuspended in PBS. Up to 106 events were
collected on an LSRFortessa ﬂow cytometer (BD Biosciences). Data
were analyzed with FlowJo (TreeStar). Cells were gated as singlets N
lymphocytes N CD4+ CD8– N cytokine positive or CD44hi N cytokine
positive. In the case of ID93, antigen-speciﬁc response frequencies
were determined by subtracting the frequency of response positives of
unstimulated cells from antigen stimulated cells.2.9. Antibody secreting cell ELISPOT assay
Antigen-speciﬁc antibody secreting cells present in the bone mar-
rowwere quantiﬁed using an ELISPOT assay. One day prior to assay ini-
tiation, Multiscreen ELISPOT plates (Millipore) were coated with 1μg of
antigen/well, and incubated overnight. Blocked plates were washed
three times with washing buffer (PBS + 0.5% Tween 20), blocked with
collection medium for 2 h, and washed 3 times. Bone marrow was col-
lected 21 days post-immunization in RPMI medium supplemented
with 10% FBS, quantiﬁed using a Guava automated cell counter
(Millipore) and resuspended to 1 × 106 cells/mL. Cells were serially di-
luted 3-fold, added to plates, and incubated for 5 h at 37 °C. Secreted an-
tibody was detected by addition of a 1:100 dilution of horse radish
peroxidase (HRP) conjugated goat anti-mouse IgG antibody (Southern
Biotech). Spots were visualized with AEC Peroxidase substrate kit
(Vector Labs) according to manufacturer's instructions. Spots were
quantitated on a CTL bioanalyzer.2.10. Innate immune response
18 h after intramuscular immunization into the gastrocnemius
muscle the draining popliteal lymphnodewas collected and dissociated
in PBS containing protease inhibitors (Thermo Fisher Scientiﬁc).
Cells were surface stained for CD8, CD90.2 (clone 53-2.1), CD19
(clone 1D3), NK1.1 (clone PK136), CD11c (clone N418), CD11b (clone
M1/70), Ly6G (clone 1A8), Ly6C (HK1.4), CD69 (clone H1·2F3), and
CD86 (clone GL1) for 20 min on ice. Cells were washed and perme-
abilized with Cytoﬁx/Cytoperm (BD Biosciences) for 20 min. Cells
were washed twice with Perm/Wash (BD Biosciences) and stained in-
tracellularly with ﬂuorochrome-labeled antibodies to IFN-γ and proIL-
1β (clone NJTEN3) (BioLegend and eBioscience) for 20 min at room
temperature. Cells were washed and resuspended in PBS. Up to 106
events were collected on an LSRFortessa ﬂow cytometer (BD Biosci-
ences). Data were analyzed with FlowJo (TreeStar). Cells were gated
as singlets N cells N CD19+ CD90.2– (B cells), CD8+ CD90.2+ (CD8 T
cells), CD8– CD90.2+ (CD4 T cells), CD8– CD19– NK1.1+ (NK cells),
CD8– CD19– CD11c+ (DCs), CD8–CD19– CD11b+ Ly6C+ (inﬂamma-
tory monocytes), or CD19–CD11b+Ly6G+ (PMNs).2.11. Statistical analysis
Antibody and T-cell responses were analyzed by two-way ANOVA
with Tukey's multiple comparison correction using Prism version 5 or
later (GraphPad). Comparisons resulting in p-values b0.05were consid-
ered signiﬁcant. Only meaningful comparisons are reported in the ﬁg-
ures (adjuvanted groups vs. antigen alone; 3M-052-Alhydrogel® vs.
Alhydrogel®, 3M-052-AF, or 3M-052-AdjuPhos®; 3M-052-AdjuPhos
vs. AdjuPhos® or 3M-052-AF).3. Results and discussion
3.1. Formulation development and physicochemical characterization
Aqueous nanosuspensions of TLR ligands are formed by adding a
suitable helper lipid or surfactant and inputting energy (e.g. sonication)
to break down the particle size of the lipid complex [21]. To determine
the most suitable helper lipid to form nanosize particles with the insol-
uble TLR7/8 ligand 3M-052, we screened a range of phospholipids and
surfactants (Fig. 1). These helper lipids were ﬁrst mixed with 3M-052
in organic solvent at a molar ratio of 1:2 (3M-052:helper lipid), based
on our previous work with a TLR4 ligand [10]. Following evaporation
of the solvent, the formulations were hydrated and sonicated to reduce
particle size. Sonication of 3M-052 without helper lipid generated a
large and heterogeneous particle size, and thus 3M-052 alone was not
employed in further physicochemical or biological studies. Several for-
mulations demonstrated acceptable particle size (b200 nm to enable
potential for terminal sterile ﬁltration) aftermanufacture as determined
by dynamic light scattering (Fig. 2A–B) and were selected for further
study. The nature of the helper lipid or surfactant dictated formulation
particle size and physical stability. Some formulations had grown signif-
icantly in size (DLPC, DOPC, polysorbate 80) indicating formulation
physical instability while others demonstrated little change (DSPG,
DSTAP) upon storage at 5 °C for 2 weeks (Fig. 2C). Most of the formula-
tionswere positively charged (Fig. 2D), as expected due to the chemical
structure of imdazoquinolines such as 3M-052, which have a pKa ~7
[22]. However, DSPG caused formation of anionic particles due to the
negative charge of the phosphate group in DSPG. An anionic aqueous
suspension is of particular interest for vaccine adjuvant development
due to the potential for adsorption to aluminum oxyhydroxide, which
is the generally preferred aluminum salt for anionic recombinant pro-
tein antigens such as those employed in the present work. The DSPG-
based nanosuspension of 3M-052, hereafter denoted 3M-052-AF, was
physically stable for at least 6 months at 4 °C, showing little change in
average particle size or particle size polydispersity (Fig. S1). Additional
studies showed that phospholipids with the same headgroup as DSPG
but different acyl chain length or saturation (Fig. 1) also promoted
nanosuspension formation and adsorption of 3M-052 to aluminum
oxyhydroxide (Table S1). DSPG was selected for further study since its
acyl chain structure (saturated 18-carbon chain) matches that of 3M-
052, although other PG-based lipidsmay be suitable for nanosuspension
formation.
The morphology of 3M-052-AF as characterized by cryoTEM indi-
cates a large percentage ofmicellar structures ~5–15 nm in diameter, al-
though larger irregularly shaped particles and vesicles were also
present (Fig. 3A–B). These size characteristics may appear to contradict
the dynamic light scattering indicated above, where Z-ave values were
generally over 100 nm. However, the light scattering intensity-based
Z-ave value reported by dynamic light scattering is heavily inﬂuenced
by even a small proportion of large particles since they scatter more
light than smaller particles (light scattering is proportional to 106 of
the particle diameter) as evident in Fig. 3C. Mathematical conversion
of the intensity based size distribution to a volume-based size distribu-
tion indicates many more particles in the ~20 nm range, although even
volume-based size distributions are also skewed by larger particles,
with a proportionality of 103 (Fig. 3D). Nevertheless, the volume-
based size distribution of 3M-052-AF is more consistent with the
cryoTEM results (Figs. 3D and 2B).
To determine the adsorption capacity of Alhydrogel® for 3M-052-
AF, the nanosuspension at various concentrations was mixed with alu-
minum oxyhydroxide and allowed to sit for ~30 min with intermittent
vortexing, followed by centrifugation such that the aluminum particles
pelleted. The supernatant was then assayed for 3M-052 to detect un-
bound material (Fig. 4). The adsorption capacity of the nanosuspension
was ~0.18 mg per mg of aluminum. The doses of 3M-052 employed in
the subsequent mouse immunogenicity experiments described in this
Fig. 2. Physical properties of aqueous suspensions of 3M-052 and adsorption to aluminum salts. (a) Light scattering intensity-based particle size (Z-ave) and polydispersity index of 3M-
052 aqueous suspensions at time ofmanufacture (shown is average± s.d. of threemeasurements from same sample). (b) Volume-basedmean particle size of the same samples based on
mathematical conversion of light scattering intensity. (c) Light scattering intensity-based particle size stability over 2 weeks for selected 3M-052 suspensions stored at 5 deg C (shown is
average ± s.d. of three measurements from same sample). (d) Zeta potential of selected 3M-052 suspensions (shown is average ± s.d. of nine measurements from the same sample for
zeta potential).
0
2
4
6
8
10
12
1 10 100 1000
In
te
n
s
ity
 
(P
e
rc
e
n
t)
Size (d.nm)
Size Distribution by Intensity
0
5
10
15
20
1 10 100 1000
V
o
lu
m
e
 (P
e
rc
e
n
t)
Size (d.nm)
Size Distribution by VolumeD
C
100nm
A
B
Fig. 3. Particle size characteristics and morphology of 3M-052-AF. (A,B) CryoTEM images at two magniﬁcations where the image shown in B (110,000×) represents the boxed area in A
(52,000×); micelle-type structures are shown by the yellow circles; larger angular structures are indicated by the white circle; vesicle-type structures are indicated by the red circle; and
particle aggregates are represented by the orange circle, scale bar = 100 nm. (C) intensity-based light scattering size distribution, (D) volume-based light scattering size distribution.
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Fig. 4. Adsorption isotherm of 3M-052-AF to Alhydrogel® as measured by UV absorbance
of supernatant. Error bars represent standard deviation from three separate experiments
using different batches of 3M-052-AF, where each sample preparation from each
experiment was performed in duplicate.
103C.B. Fox et al. / Journal of Controlled Release 244 (2016) 98–107workwerewell below 0.18mg3M-052 permg of aluminum. Due to the
small particle size of the 3M-052-AF, the nanosuspension particles were
not evident in the cryoTEM images containing aluminum oxyhydroxide
(Fig. 5A–B). Indeed, the morphology of the aluminum oxyhydroxide
particles appeared much the same regardless of whether 3M-052-AF
was present, with the notable exception that the crystalline aggregates
appeared larger in size in the sample containing 3M-052-AF compared
to the aluminum oxyhydroxide control.
The adsorption stability of 3M-052-AF on Alhydrogel® over time
was evaluated by assaying samples for unbound 3M-052-AF before
and after storage at 5 °C for 16 wks. Although there appeared to be par-
tial loss of 3M-052-AF in the supernatants of the controls, there was no
increase in detectable 3M-052-AF in the supernatants of Alum-
containing samples, indicating no desorption over 16 wks (Table S2).
Moreover, the presence of other TLR ligands did not appear to interfere
with the adsorption of 3M-052-AF to aluminum oxyhydroxide, indicat-
ing that an Alum-based formulation containing multiple adsorbed
PRR ligands could be feasible (Table S2). In contrast to aluminumFig. 5.Aluminumoxyhydroxidemorphology (with orwithout 3M-052-AF). (A) cryo-TEM
image of aluminum oxyhydroxide particles, and (B) cryo-TEM image of aluminum
oxyhydroxide particles with 3M-052-AF. Scale bar = 500 nm (left images) or 100 nm
(right images).oxyhydroxide, we did not observe binding of 3M-052-AF to aluminum
phosphate.
To determine whether 3M-052-AF adsorbed to aluminum
oxyhydroxide via a ligand exchange or electrostatic mechanism we
evaluated the effect of ionic strength on adsorption, which neutralizes
electrostatic mediated binding [23]. A trend of decreasing 3M-052-AF
content in the supernatant of the control samples with increasing sodi-
um chloride concentration is attributable to a rapid increase in particle
size of 3M-052-AF upon exposure to saline, resulting in pelleting of
the nanosuspension even when the aluminum was not present
(Table S3). Nevertheless, increasing sodium chloride concentration did
not appear to reduce the binding of 3M-052-AF to aluminum
oxyhydroxide, indicating a ligand exchange mechanism rather than
an electrostatic mechanism. Thus, by appropriate selection of helper
lipid, the adsorption of 3M-052-AF to aluminum oxyhydroxide was
facilitated.
Recent seminal work by Wu et al. demonstrated that chemical syn-
thesis of new TLR7 ligandswith phosphonate groups facilitated adsorp-
tion to aluminum oxyhydroxide, resulting in improved transient
localized adjuvant activity while reducing systemic activation [8].
Alum-adsorbed TLR7 formulations effectively boosted antibody magni-
tude and quality to various vaccine antigens, including enhanced pro-
tection against challenge compared to the antigen with Alum alone or
the TLR7 ligand alone [8]. In contrast, the formulation approach de-
scribed herein does not require phosphonate groups on the PRR ligand
to facilitate adsorption of PRR ligands to aluminum salts, and thus may
have broader applicability. The ability to promote adsorption of PRR li-
gands to aluminum salts could provide a signiﬁcant development ad-
vantage from a regulatory standpoint, since an alum-adsorbed PRR
ligand formulation is already contained in approved vaccines such as
Cervarix®. Importantly, a formulation-based approach could avoid the
need to chemically modify existing agonist structures, relying instead
on the properties of the formulation to promote adsorption to alumi-
num salts.Moreover, lipid formulationmodiﬁcations could tailor PRR li-
gand adsorption preference to speciﬁc aluminum salts such that vaccine
antigen and PRR ligand could be adsorbed to the same type of aluminum
salt. Such excipient properties include length and saturation of acyl
chains and headgroup structure/charge. We found that the latter ap-
peared to be themain determinant in the ability of the nanosuspension
to adsorb to aluminum salts, although acyl chain structure should also
be taken into account in order to ensure stable suspension formation
between PRR ligand and helper lipid.
3.2. Adjuvant biological activity
To determine whether the binding of 3M-052-AF to aluminum
oxyhydroxide alters the in vivo adjuvanticity of aluminumoxyhydroxide
or 3M-052-AF, we immunized C57BL/6 mice with the tuberculosis vac-
cine antigen ID93 [18] without adjuvant or adjuvanted with either 3M-
052-AF, aluminum oxyhydroxide, or 3M-052-AF bound to aluminum
oxyhydroxide. Three weeks after the ﬁrst immunization, mice receiving
ID93+3M-052-AF-Alhydrogel® exhibited the highest serum titers of
ID93-speciﬁc total IgG as well as IgG1 and IgG2c subtypes indicating
that 3M-052-AF-Alhyrogel has unique adjuvant properties compared
to either 3M-052-AF or Alhydrogel® alone (Fig. 6A). One month after
the third immunization we assessed CD4 T cell responses by stimulating
splenocytes with ID93 and measuring cytokine production in the pres-
ence of Brefeldin A by ﬂow cytometry. Compared to mice immunized
with ID93 alone, both ID93+3M-052-AF and ID93+3M-052-AF-
Alhydrogel® immunized mice had greater frequencies of ID93-speciﬁc
CD4 T cells expressing CD154. Importantly, only the mice immunized
with ID93+3M-052-AF-Alhydrogel® exhibited TH1 cells that made
IFN-γ, TNF, IL-2 and GM-CSF upon ID93 stimulation (Fig. 6B).
While the Th1-type response to 3M-052-AF-Alhydrogel® was gen-
erally consistent across multiple experiments, we note that there was
more variability in biological response to 3M-052-AF (without
Fig. 6. Alhydrogel® and 3M052-AF induce synergistic antigen-speciﬁc immunogenicity. C57BL/6 mice were immunized three times, three weeks apart via intramuscular injection with
ID93 (0.5 μg) alone or adjuvanted with 3M-052-AF (0.5 μg), Alhydrogel®, or 3M-052-AF (0.5 μg) bound to Alhydrogel®. (A) Three weeks after the ﬁrst immunization ID93-speciﬁc
IgG1, IgG2c, and total IgG (IgGT) serum endpoint titers were determined by ELISA. N = 4–5 mice/group. (B) Four weeks after the ﬁnal immunization splenocytes were restimulated
with media or ID93 in the presence of Brefeldin A for 8 h and the frequency of cytokine producing CD4 T cells was determined by subtracting the media response from the ID93-
speciﬁc response. Data are representative of two experiments with similar results with 4–5 animals per group. Mean ± s.e.m. is shown. *p b 0.05 vs. ID93, #p b 0.05 vs. ID93 + 3M-
052-AF, †p b 0.05 vs. ID93-Alhydrogel®.
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juvant activity comparable to 3M-052-AF-Alhydrogel® (data not
shown). Adsorption of 3M-052-AF to Alhydrogel® appeared to result
in a more consistent biological activity between batches. Signiﬁcant
variation in biological response upon seemingly minor changes in for-
mulation properties was also noted earlier for another aqueous
nanosuspension, GLA-AF, from our lab [24]. For GLA-AF, we showed
that systematically varying the phospholipid:TLR4 ligand ratio revealed
a dramatic bi-phasic response in physicochemical as well as in vitro bio-
activity assays [24]. Thus, if the phospholipid:3M-052 ratio employed in
the present work is near such an inﬂection point, seemingly minor var-
iations in the preparation or physical properties of the formulation
could result inmajor changes in its biological activity. The effects of pro-
cessing conditions, diluents, and vaccine antigen properties on the het-
erogeneous particle characteristics of 3M-052-AF also merit further
investigation, which is ongoing in our lab.Fig. 7. 3M-052-AF and 3M052-AF-Alhydrogel® dose titration. C57BL/6mice were immunized t
with 3M-052-AF (0.1, 0.5, 1, or 10 μg), Alhydrogel®, or 3M-052-AF (0.1, 0.5, 1, or 10 μg) bound t
total IgG serumendpoint titersweredetermined byELISA.N=5mice/group. (B)Oneweek afte
of Brefeldin A for 8 h and the frequency of cytokine producing CD4 T cells was determined by s
two experiments with similar results with 5 animals per group. Mean ± s.e.m. is shown.To determine whether binding 3M-052-AF to aluminum
oxyhydroxide fundamentally changed its adjuvant activity or simply al-
tered its bioavailability we examined the adjuvant activity of 3M-052-
AF alone or bound to aluminum oxyhydroxide over a two log10 dose
range. Three weeks after the ﬁrst immunization with adjuvanted ID93
the Alum-adsorbed formulation of 3M-052-AF consistently elicited
higher serum antibody titers across the entire dose range compared
to either Alhydrogel® alone or the same dose range of 3M-052-AF
(Fig. 7A). Similarly 3M-052-AF-Alhydrogel® demonstrated a bell
shaped dose response for augmenting ID93-speciﬁc CD4 T cells with
the peak response of the tested doses at 1 μg. These CD154 and IFN-γ re-
sponses were substantially higher than those elicited with ID93
adjuvanted with aluminum oxyhydroxide or 3M-052-AF at 0.1, 1, or
10 μg (Fig. 7B). Similar dose responses were observed for TNF and IL-2
producing CD4 T cells as well (data not shown). Based on this we con-
clude that binding 3M-052-AF to aluminum oxyhydroxide alters itswice three weeks apart via intramuscular injection with ID93 (0.5 μg) alone or adjuvanted
o Alhydrogel®. (A) Threeweeks after the ﬁrst immunization ID93-speciﬁc IgG1, IgG2c, and
r theﬁnal immunization splenocyteswere restimulatedwithmedia or ID93 in thepresence
ubtracting the media response from the ID93-speciﬁc response. Data are representative of
105C.B. Fox et al. / Journal of Controlled Release 244 (2016) 98–107adjuvant activity by some means other than simply changing the bio-
availability over a 1 log10 range in either direction.
In vitro, 3M-052 (dissolved in DMSO) activates human TLR7 and
TLR8 [16]. To determine whether these innate immune receptors are
important for the in vivo adjuvant activity of 3M-052-AF-Alhydrogel®
we compared the immune response of vaccinated wild type (WT)
C57BL/6 mice and mice lacking TLR7 (C57BL/6 mice express a
hypofunctional TLR8). As a control we also immunized C57BL/6 and
TLR7-/- mice with ID93 adjuvanted with the TLR4 agonist adjuvant
GLA-AF-Alhydrogel®. All of the immunized groups produced high titers
of ID93-speciﬁc IgG1 antibodies, regardless of adjuvant or genotype
(Fig. 8A). Both 3M-052-AF-Alhydrogel® and GLA-AF-Alhydrogel® also
elicited high titers of IgG2c in C57Bl/6 mice compared to Alhydrogel®
alone. In TLR7-/- mice the IgG2c induction was drastically reduced in
animals immunized with ID93+3M-052-AF-Alhydrogel®, whereas
the IgG2c response to ID93+GLA-AF-Alhdyrogel® was not affected by
TLR7 deﬁciency, conﬁrming that TLR7 was necessary to recognize 3M-
052, but not Alhydrogel® or GLA. ID93+3M-052-AF-Alhdyrogel® also
elicited robust cellular responses in WT mice characterized by CD4 T
cells capable of producing IFN-γ and TNF with very little IL-5 or IL-17A
produced (markers of TH2 and TH17 immunity, respectively). However
in TLR7-/- mice ID93+3M-052-AF-Alhydrogel® elicited only minor
CD4 T cell responses to ID93 which were not substantially different in
magnitude from the responses elicited by ID93 adjuvanted with
Alhydrogel® alone in WT mice (Fig. 8B). Immunization of WT and
TLR7-/- mice with ID93+GLA-AF-Alhydrogel® elicited similar TH1 re-
sponses indicating that TLR7-/- mice are not impaired in their CD4 T
cell response to vaccines with other TLR agonist containing adjuvants
formulated on Alum. Therefore we conclude that similar to the in vitroFig. 8. TLR7 is required for the TH1 inducing adjuvant activity of 3M-052-AF-Alhydrogel®.
Wildtype C57BL/6 or B6.129S1-TLR7tm1Flv (TLR7-/-) mice were immunized twice three
weeks apart via intramuscular injection with ID93 (0.5 μg) adjuvanted with
Alhydrogel®, 3M-052-AF (1 μg) bound to Alhydrogel®, or GLA-AF (5 μg) bound to
Alhydrogel®. (A) ID93-speciﬁc IgG1 and IgG2c serum antibody titers were determined
three weeks after the ﬁrst immunization. (B) ID93-speciﬁc CD4 T cells were quantiﬁed
following ex-vivo stimulation of splenocytes with ID93 one week after the second
immunization. N = 5 mice/group. Data are representative of two experiments with
similar results with 5 animals per group. Bars indicate mean ± s.e.m. *p b 0.05.ﬁndings, 3M-052-AF-Alhydrogel® requires TLR7 for its in vivo adjuvant
activity, particularly in eliciting high frequencies of TH1 CD4 T cells and
IgG2c switched antibody responses.
As noted above, we have previously employed the helper lipid ap-
proach to adsorb TLR4 ligands to aluminum oxyhydroxide. The other-
wise insoluble TLR4 ligand GLA can be formulated as an aqueous
suspension using a helper lipid, which can then be mixed with alumi-
num oxyhydroxide to allow for adsorption. However, in the case of
GLA the agonist itself contains a phosphate group which promotes ad-
sorption through ligand exchange. In the case of 3M-052, the agonist
contains no phosphate group, thus adsorption due to ligand exchange
must be entirely attributed to the helper lipid. Although in the present
study ID93+3M-052-AF-Alhydrogel® appeared to induce a more po-
tent TH1 response than ID93+GLA-AF-Alhydrogel® (Fig. 8), further in-
vestigation along these lines is merited. Cellular location and
distribution of TLR7/8 and TLR4 is signiﬁcantly different and varies be-
tween species [13]. For example, TLR8 is considered refractory in
mice; thus, an agonist such as 3M-052may elicit altered or enhanced re-
sponses in humans or other species with functional TLR8. Such consid-
erations, combined with the data presented here, indicate that an
Alum-based TLR7/8 adjuvant formulation could provide a potent adju-
vant formulation for TH1 responses in humans.
To test the in vivo adjuvant activity of 3M-052-AF with a different
vaccine antigen as well as the effect of different aluminum salts, we im-
munized C57BL/6 mice with the HIV vaccine antigen FLSC [19]
adjuvanted with either 3M-052-AF, aluminum oxyhydroxide, alumi-
num phosphate, or 3M-052-AF in combination with aluminum
oxyhydroxide or aluminum phosphate. Three weeks after the ﬁrst im-
munization, themost elevated serum IgG and IgG2c antibody responses
were elicited by FLSC adjuvanted with 3M-052-AF-Alhydrogel®
(Fig. 9A). Interestingly, 3M-052-AF-Alhydrogel® also produced the
highest levels of mucosal IgG2c and antibody-secreting long lived plas-
ma cells (Figs. 9C and S3). Moreover, the formulation containing 3M-
052-AF and Alhydrogel® was the most potent inducer of IFNγ and
TNF from CD4+ T cells (Fig. 9B), particularly one week after the
prime immunization (Fig. S2). Overall, 3M-052-AF-Alhdyrogel® ap-
peared to have more potent adjuvant activity in this model than 3M-
052-AF-AdjuPhos®; however, since the FLSC antigen under these condi-
tions adsorbs to aluminum oxyhydroxide (Alhydrogel®) but not alumi-
num phosphate (AdjuPhos®) (Fig. S3), reduced immunogenicity
responses could be attributable to less optimal adsorption of both anti-
gen and/or 3M-052-AF to aluminum phosphate.
Induction of a robust adaptive immune response to vaccine antigens
requires appropriate activation of the innate immune system to provide
the necessary costimulatory and cytokinemilieu. Thus we analyzed the
innate immune responses in the draining lymph node that are altered
by immunization with 3M-052-AF ± aluminum phosphate or alumi-
num oxyhydroxide. Although not statistically signiﬁcant in all readouts,
overall 3M-052-AF synergized with aluminum oxyhydroxide to en-
hance various innate immune responses (Fig. 10). Thus, 3M-052-AF ap-
peared to synergizewith aluminumoxyhydroxide and to a lesser extent
aluminumphosphate to elicit a robust increase in the number of inﬂam-
matory monocytes (CD11b+ Ly6C+) in the draining lymph node 18 h
after i.m. injection (Fig. 10A). Similarly 3M-052-AF and both Alum for-
mulations augmented expression of the co-stimulatory molecule CD86
on APCs including B cells, monocytes and dendritic cells and transient
activation of CD4 and CD8 T cells as well as B cells as indicated by
CD69 expression (Fig. 10B and C). 3M-052-AF uniquely synergized
with aluminum oxyhydroxide to augment number of NK cells express-
ing IFN-γ and showed trend of increased neutrophils producing IL-1
(Fig. 10D), both molecules important for the induction of robust TH1
responses with vaccine adjuvants [25]. This innate response to
the synergy between 3M-052-AF and Alum likely creates the appropri-
ate environment for the robust generation of adaptive immune
responses to the vaccine antigens. The expansion of IFN-γ producing
NK cells and IL-1 producing neutrophils correlates with the stronger
Fig. 9. FLSC formulatedwith 3M-052-AF-Alhydrogel® induces enhanced antibody and TH1-type cellular responses compared to FLSC formulatedwith 3M-052-AF-AdjuPhos®, 3M-052-AF
alone, or either type of Alum alone. C57BL/6 mice were immunized three times, three weeks apart via intramuscular injection with FLSC (10 μg) alone or adjuvanted with 3M-052-AF
(1 μg), Alhydrogel®, AdjuPhos®, 3M-052-AF-Alhydrogel®, or 3M-052-AF-AdjuPhos®. (A) Three weeks after the ﬁrst immunization FLSC-speciﬁc IgG1, IgG2c, and total IgG (IgG)
serum endpoint titers were determined by ELISA. N= 5 mice/group, bars indicate mean + s.d. (B) One week after the second immunization splenocytes were restimulated with FLSC
and the frequency of cytokine producing CD4 T cells was determined by ﬂow cytometry. N = 5 mice/group, bars indicate mean ± s.d. (C) Three weeks after the second and
third immunizations FLSC-speciﬁc bone marrow antibody-secreting cells were measured by ELISPOT. N = 5 mice/group, bars indicate mean ± s.e.m. *p b 0.05 vs. FLSC, #p b 0.05 vs.
3M-052-AF, †p b 0.05 vs. corresponding Alum (Alhydrogel® or AdjuPhos®), ‡p b 0.05 vs. 3M-052-AF-AdjuPhos®.
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to the weaker responses induced by 3M-052-AF + aluminum
phosphate.Fig. 10. 3M-052-AF andAlumsynergize to augment innate responses upon immunization.Wild
AdjuPhos®, 3M-052-AF-Alhydrogel®, or 3M-052-AF-AdjuPhos®. 18 h later the draining i
inﬂammatory monocytes, (B) expression of the costimulatory molecule CD86 on B cells, inﬂa
of IFN-γ or IL-1b by NK cells and neutrophils, respectively. N= 5 mice/group. Data are repres
mean + s.e.m. *p b 0.05 vs. none, #p b 0.05 vs. 3M-052-AF, †p b 0.05 vs. corresponding Alum (3M-052-AF and aluminumhydroxide synergized to increase expres-
sion of the co-stimulatory molecule CD86 on APCs in the draining LN
and to transiently activate lymphocytes to remain in the drainingtype C57BL/6micewere immunized intramuscularlywith 3M-052-AF (1 μg), Alhydrogel®,
nguinal lymph nodes were harvested and analyzed for (A) inﬂux of CD11b + Ly6C+
mmatory monocytes or DCs (C) expression of CD69 on lymphocytes, and (D) expression
entative of two experiments with similar results with 5 animals per group. Bars indicate
Alhydrogel® or AdjuPhos®), ‡p b 0.05 vs. 3M-052-AF-AdjuPhos®.
107C.B. Fox et al. / Journal of Controlled Release 244 (2016) 98–107lymph node in an antigen-independent fashion. By activating APCs and
trapping lymphocytes in the same draining LN this synergy creates an
optimal environment for lymphocyte priming and expansion. Interest-
ingly, innate responses including early production of IFN-γ and IL-1β
which we found to be important for the adjuvanticity of the GLA-SE
[25] were also most pronounced when 3M-052-AF was formulated
with aluminum oxyhydroxide. This may suggest that these parameters
could be useful universal signatures of effective adjuvant activity. Iden-
tiﬁcation of such signatures would aid the rational development of new
vaccine candidates.
4. Conclusion
In summary, we have developed a method to formulate lipid-based
PRR ligands into aqueous nanosuspensions that can be made to adsorb
to aluminum salts based on the properties of the helper lipid. The ability
to develop Alum-compatible formulations of new PRR ligands may
enable more rapid translation to the clinic since such formulations
are analogous to the TLR4 ligand-Alum combination employed in
Cervarix®, and aluminum salts are the most widely employed class of
adjuvants in human vaccines, with a well-established safety and immu-
nogenicity record.
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